NCT00843193 - Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

December 9, 2008

Primary Completion Date

July 25, 2010

Study Completion Date

July 25, 2010

Conditions

Asthma

Interventions

DRUG

INTRAVENOUS GSK679586

GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump

DRUG

INTRAVENOUS PLACEBO

Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump

DRUG

FLUTICASONE PROPIONATE

Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.

Trial Locations (35)

2408

GSK Investigational Site, Elverum

7006

GSK Investigational Site, Trondheim

7505

GSK Investigational Site, Cape Town

7530

GSK Investigational Site, Bellville

7700

GSK Investigational Site, Mowbray

9301

GSK Investigational Site, Bloemfontein

13009

GSK Investigational Site, Marseille

29118

GSK Investigational Site, Orangeburg

34295

GSK Investigational Site, Montpellier

39112

GSK Investigational Site, Magdeburg

44093

GSK Investigational Site, Nantes

53792

GSK Investigational Site, Madison

60596

GSK Investigational Site, Frankfurt am Main

63571

GSK Investigational Site, Gelnhausen

65013

GSK Investigational Site, Tarbes

67091

GSK Investigational Site, Strasbourg

78006

GSK Investigational Site, Boerne

97213

GSK Investigational Site, Portland

97448

GSK Investigational Site, Saint-Pierre

97504

GSK Investigational Site, Medford

PA 15213

GSK Investigational Site, Pittsburgh

59037 cedex

GSK Investigational Site, Lille

5623 EJ

GSK Investigational Site, Eindhoven

6419 PC

GSK Investigational Site, Heerlen

1624 NP

GSK Investigational Site, Hoorn

15-276

GSK Investigational Site, Bialystok

97-540

GSK Investigational Site, Gidle

31-023

GSK Investigational Site, Krakow

90-153

GSK Investigational Site, Lodz

02-097

GSK Investigational Site, Warsaw

SO16 6YD

GSK Investigational Site, Southampton

GU2 7XP

GSK Investigational Site, Guildford

BT9 7AB

GSK Investigational Site, Belfast

SE1 1YR

GSK Investigational Site, London

NG5 1PB

GSK Investigational Site, Nottingham